CSIMarket
 


Neurocrine Biosciences Inc  (NBIX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

NBIX's Revenue Growth by Quarter and Year

Neurocrine Biosciences Inc's Revenue results by quarter and year




NBIX Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - -196.58 94.52 -
III Quarter September - 151.76 60.77 -
II Quarter June - 96.91 6.34 -
I Quarter March 138.40 71.09 - 15.00
FY   138.40 123.18 161.63 15.00



NBIX Revenue first quarter 2019 Y/Y Growth Comment
Neurocrine Biosciences Inc achieved in the first quarter, above Company average Revenue rise of 94.69% year on year, to $ 138.40 millions.

According to the results reported in the first quarter, Neurocrine Biosciences Inc achieved the best Revenue growth in Biotechnology & Drugs industry. While Neurocrine Biosciences Inc' s Revenue jump of 94.69% ranks overall at the positon no. 4 in the first quarter.




NBIX Revenue ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - 149.73 % - -
II Quarter June - 1428.55 % - -
I Quarter March 94.69 % - - -24.13 %
FY   - -23.79 % 977.53 % -

Financial Statements
Neurocrine Biosciences Inc's first quarter 2019 Revenue $ 138.40 millions NBIX's Income Statement
Neurocrine Biosciences Inc's first quarter 2018 Revenue $ 71.09 millions Quarterly NBIX's Income Statement
New: More NBIX's historic Revenue Growth >>


NBIX Revenue (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - - 55.54 % -
III Quarter September - 56.6 % 858.52 % -
II Quarter June - 36.32 % - -
I Quarter March - -24.79 % - -
FY (Year on Year)   - -23.79 % 977.53 % -




Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #1
Healthcare Sector #1
Overall #4

Revenue Y/Y Growth Statistics
High Average Low
54.66 % 5.02 % -70.27 %
(Mar 31 2019)   (Dec 31 2018)
Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #1
Healthcare Sector #1
Overall #4
Revenue Y/Y Growth Statistics
High Average Low
54.66 % 5.02 % -70.27 %
(Mar 31 2019)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Neurocrine Biosciences Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
859.34 % 61.53 % -100 %
(Sep 30 2017)  


NBIX's I. Quarter Q/Q Revenue Comment
This turnaround I. Quarter 2019where Neurocrine Biosciences Inc delivered Revenue of $ 138.40 millions may is starting point of improved performance.Neurocrine Biosciences Inc announced in the I. Quarter 2019 Revenue of $ 138.40 millions compare to recorded in previos quarter.

Within Biotechnology & Drugs industry Neurocrine Biosciences Inc achieved highest sequential Revenue growth. While Neurocrine Biosciences Inc's Revenue growth quarter on quarter, overall rank is 0.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #0
Revenue Q/Q Growth Statistics
High Average Low
859.34 % 61.53 % -100 %
(Sep 30 2017)  


NBIX's I. Quarter Q/Q Revenue Comment
This reversal of fortune I. Quarter 2019where Neurocrine Biosciences Inc published Revenue of $ 138.40 millions could be beginning of improved business climet.Neurocrine Biosciences Inc announced in the I. Quarter 2019 Revenue of $ 138.40 millions compare to recorded in previos quarter.

Within Biotechnology & Drugs industry Neurocrine Biosciences Inc achieved highest sequential Revenue growth. While Neurocrine Biosciences Inc's Revenue growth quarter on quarter, overall rank is 0.


Neurocrine Biosciences Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec. 30, 2014)
12 Months Ending
(Sep. 30, 2014)
12 Months Ending
(June 30. 2014)
12 Months Ending
(March 31, 2014)
Cumulative Revenue 12 Months Ending $ 190.48 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) -18.15 % - - - -
Year on Year Revenue Growth Overall Ranking # 1276 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 54.66 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 62 # 47 # 169 # 116 # 0




Cumulative Revenue growth Comment
Neurocrine Biosciences Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec. 30, 2014. If the fiscal year would end in Mar 31 2019, Neurocrine Biosciences Inc's annual Revenue rise would be -18.15% year on year to $190 millions.

In the Healthcare sector 123 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1276.

Revenue TTM Q/Q Growth Statistics
High Average Low
54.66 %
14.16 %
-26.33 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 7
Healthcare Sector # 124
Overall # 1276

Revenue TTM Y/Y Growth Statistics
High Average Low
-18.15 %
-22.24 %
-26.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 15
S&P 500 # 62
Cumulative Revenue growth Comment
Neurocrine Biosciences Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec. 30, 2014. If the fiscal year would end in Mar 31 2019, Neurocrine Biosciences Inc's annual Revenue drop would be -18.15% year on year to $190 millions.

In the Healthcare sector 123 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1276.

Revenue TTM Q/Q Growth Statistics
High Average Low
54.66 %
14.16 %
-26.33 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 7
Healthcare Sector # 124
Overall # 1276

Revenue TTM Y/Y Growth Statistics
High Average Low
-18.15 %
-22.24 %
-26.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 15
S&P 500 # 62




Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBIX's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NBIX's Competitors
Revenue Growth for Neurocrine Biosciences Inc's Suppliers
Revenue Growth for NBIX's Customers

You may also want to know
NBIX's Annual Growth Rates NBIX's Profitability Ratios NBIX's Asset Turnover Ratio NBIX's Dividend Growth
NBIX's Roe NBIX's Valuation Ratios NBIX's Financial Strength Ratios NBIX's Dividend Payout Ratio
NBIX's Roa NBIX's Inventory Turnover Ratio NBIX's Growth Rates NBIX's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Mar 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2019
Myomo Inc  165.05 %$ 165.045 millions
Myos Rens Technology Inc.  161.40 %$ 161.404 millions
Northwest Biotherapeutics Inc  156.82 %$ 156.818 millions
Fate Therapeutics Inc  156.53 %$ 156.530 millions
Tandem Diabetes Care Inc  141.94 %$ 141.944 millions
Beigene, Ltd.  139.16 %$ 139.162 millions
Accelerate Diagnostics, Inc.  118.48 %$ 118.477 millions
Techcare Corp.  117.69 %$ 117.690 millions
Eyepoint Pharmaceuticals, Inc.  116.81 %$ 116.810 millions
Wave Life Sciences Ltd.  112.80 %$ 112.799 millions
Cytomx Therapeutics, Inc.  107.88 %$ 107.875 millions
Yield10 Bioscience, Inc.  106.67 %$ 106.667 millions
Pieris Pharmaceuticals, Inc.  105.80 %$ 105.804 millions
Ionis Pharmaceuticals Inc  105.80 %$ 105.800 millions
Radius Health, Inc.  105.16 %$ 105.156 millions
Corindus Vascular Robotics, Inc.  104.44 %$ 104.444 millions
Amicus Therapeutics, Inc.  103.92 %$ 103.917 millions
Vilacto Bio Inc.  103.61 %$ 103.613 millions
Akers Biosciences, Inc.  102.37 %$ 102.371 millions
Vbi Vaccines Inc  102.25 %$ 102.247 millions
Dicerna Pharmaceuticals Inc  101.10 %$ 101.100 millions
Corbus Pharmaceuticals Holdings, Inc.  98.40 %$ 98.401 millions
Jaguar Health, Inc.  97.64 %$ 97.640 millions
Neurocrine Biosciences Inc  94.70 %$ 94.698 millions
Precision Optics Corporation, Inc.  88.48 %$ 88.480 millions
Inovio Pharmaceuticals, Inc.  85.00 %$ 85.004 millions
Caredx, Inc.  84.89 %$ 84.886 millions
Cv Sciences, Inc.  84.75 %$ 84.753 millions
Halozyme Therapeutics Inc.  84.47 %$ 84.468 millions
Seres Therapeutics, Inc.  84.36 %$ 84.362 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

APEX's Profile

Stock Price

APEX's Financials

Business Description

Fundamentals

Charts & Quotes

APEX's News

Suppliers

APEX's Competitors

Customers & Markets

Economic Indicators

APEX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071